Abstract
Background and Aims : Lipoprotein(a) [Lp(a)] contributes to atherogenesis, reduces fibrinolysis leading to thrombogenesis and increases pro-inflammatory response. Extreme levels of Lp(a) are associated with an increased risk of cardiovascular mortality, coronary heart disease, peripheral artery disease and stroke in primary prevention. Whether extreme Lp(a) is associated with sub-clinical atherosclerotic cardiovascular disease (sASCVD) has not been described yet. The aim of this study was to assess sASCVD in patients with extreme Lp(a) levels in primary prevention.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
